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ABSTRACT
The controversy surrounding the different interpretations on the integrality of therapeutic and 
pharmaceutical care has led to the delimitation of its scope by a law, but the issue has not been 
completely pacified. As a contribution to this debate, we aim to discuss the challenges to ensure 
the integrality of the therapeutic and pharmaceutical care, based on a conceptual approach on 
the meanings of integrality in the Brazilian Unified Health System (SUS). We identified important 
challenges to ensure the integrality of the therapeutic and pharmaceutical care in the SUS. These 
challenges are related to professional practices, the organization of actions and services, and the 
governmental response to health problems or to the treatment of specific population groups. For 
this end, governments need to carry out structuring actions and be efficient in using available 
resources so that existing problems can be overcome.
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INTRODUCTION
Access to essential drugs is considered an important public policy tool to improve the quality 
of life of populations, and the appropriate use of these drugs is one of the most cost-effective 
components of health carea. The access to them demands the articulation of a set of actions and 
services within the health system, as well as broader governmental actions, such as the promotion 
of research, development of drugs, and the sanitary and economic regulation of the market.
In Brazil, this set of actions and services was called pharmaceutical careb and gained 
prominence in the national public debate since the mid-2000s, when extended judicial 
decisions determined the supply of medicines to citizens by the managers of the Brazilian 
Unified Health System (SUS). The issue of the integrality of therapeutic care (ITC) is at the 
heart of this debate, with different interpretations on its impacts, leading to the delimitation 
of its scope, without solving the issuec.
Less discussed is the integrality of the pharmaceutical care (IPC). What it means, what is 
its scope, and how to ensure them are issues that need to be analyzed and this seems to be 
an opportune moment, since ideas are presented to replace the dispensation of drugs in 
the primary health care in the SUS by private pharmaceutical establishments, in a model 
similar to that of the Popular Pharmacy Program.
As a contribution to this debate, we aim to discuss the challenges to ensure the integrality 
of the therapeutic and pharmaceutical care (ITPC), based on a conceptual approach on the 
meanings of integrality of the health care in the SUS.
Universality and Integrality of the Access to Health Actions and Services
The Brazilian Federal Constitution establishes the integrality of care in the SUS as one of the 
guidelines of the system, focusing on preventive activities and without impairment of the 
care servicesd. Subsequently, it was defined that comprehensive therapeutic care, including 
pharmaceutical care, is included in the field of activity of the SUSe.
Mattos1,2 discusses three sets of meanings related to integrality, regarding: (i) the practices 
of health professionals, in which there is a concern to discern the needs of users, (ii) the 
organization of health services and practices, because they must be organized to achieve 
a broader understanding of the needs of the population, the link between prevention and 
care, and the continuous organization of work processes, and (iii) government responses to 
certain health problems or the needs of specific groups.
Under the SUS, this broader understanding of integrality appears to be a reality. However, 
the phenomenon of health judicialization has shown that, in a more general social context, 
this is not a hegemonic interpretation3, something that has worried health managers by the 
expressive number of lawsuitsf.
It is clear that the increase in the legal demands for drugs shows greater access of the 
population to the Judicial Branch and greater awareness about the right to health4. It also 
indicates that a significant part of the requests refers to pharmaceutical products that are 
present in public policies, but to which persons have difficulty accessing for different reasons5. 
However, we can also observe that if judicial decisions do not consider public policies and 
principles of the SUS, they have great potential to disorganize it6 and increase inequity in 
access to health services and actions7.
The ITC cannot be interpreted as everything for everyone, as an indiscriminate right to any 
technology. In the national or international pharmaceutical market, many drugs overlap, 
have less therapeutic potential, or present greater risks compared to others already available 
in the SUS, and they can be much more expensive.
The controversy surrounding the understanding on the ITC and the judicialization of the 
health sector motivated the approval of Law 12,401, defining integrality as the ensuring of 
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the access to drugs present in clinical protocols and in drug relations elaborated by the 
managers of the SUSc. However the passage of this law does not solve the issue. First, because 
it stresses the principle of universality, as in the case of drugs not incorporated into the SUS 
for the treatment of rare diseases8. All citizens have the right to universal and equal access 
to policies for the promotion, protection, and recovery of their health and this principle is 
understood as that which is common to all9. Second, because the Federal Supreme Court 
has already established jurisprudence on the subject, and the understanding is that: (i) the 
supply of drugs without registration in the National Health Agency (ANVISA) is only admitted 
under exceptional conditions, (ii) the separation of the Powers prohibits the possibility of a 
law replacing the registration of the drug, which is typical of the Executive Branch, (iii) it is 
necessary to observe, in principle, the protocols, (iv) however, universality must be ensured, 
and the Judicial Branch may intervene in cases of omission of the Executive Branch, and 
(v) the subjective public right to health represents an indissociable prerogative of the right 
to life10. As we can see, the ITPC involves a set of complex challenges for the Government.
Challenges to Ensure the ITPC in the SUS
The SUS also faces important problems to ensure the access and rational use of drugs to the 
population. Some evaluations of the pharmaceutical care that also bring the discussion of 
integrality show that many problems still need to be addressed11–15.
As for professional practices, the challenges of the ITPC are the training and qualification 
of pharmacists for the practice of clinical pharmacy, the recognition of their role in health 
teams, and the integrated action of other health professionals. Some initiatives have been 
successful in this sense16,g, but the dimensions of the SUS impose the need to implement 
more structuring measures in this regard, with a focus on promoting the rational use of drugs.
From the point of view of the organization of services, many municipalities also need to 
ensure: a) the timing of the procurement and distribution of drugs, b) the integration and 
communication between pharmacies, c) the availability of pharmaceutical products, d) the 
information to patients about the organization of services, e) the practice of the clinical 
pharmacy, f ) the adequate infrastructure, including computerization of pharmacies and 
supply centers, in addition to their connection with other health services, and g) the 
economicity, both in relation to drugs and the model of management of pharmaceutical care.
Regarding this last aspect, we have observed new organizational arrangements that bring 
advantages and disadvantages to the access to drugs, their rational use, and the economics 
in the SUS (Box).
Obviously, the issues surrounding models and their results are not exhausted by the few 
variables presented in the Box, which illustrates the potential fragmentation of services 
and care. It is worth noting that even if a particular health department decides to adopt 
a privatized model of dispensing drugs, it would still have to maintain services under its 
management since several drugs of the National Essential Medicine List (RENAME) are not 
marketed by drugstores, and also that the fragmentation of the care occurs in the SUS, but 
it can be aggravated in mixed models.
In addition, we highlight that the costs may be higher for the Government in the segmented 
model, in which drugstores act in the dispensing of drugs and are reimbursed by the 
Government for both the product and the service. Studies comparing the costs of offering 
drugs with the public pharmaceutical care to those of the Popular Pharmacy Program 
concluded that the costs are lower in the SUS17,18.
In the federal government, great concern about the growth of spending with the Popular 
Pharmacy Program has motivated the adoption of measures to regulate access to drugs. In 
real terms, expenditures rose 667% between 2010 and 2015, with a decrease between 2015 
and 2016, when they went from R$3 billion to R$2.7 billion in 2016, from the negotiation of 
prices made by the Ministry of Health (Figure).
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In the same period, the Components of the Pharmaceutical Care Financing Block had a 
much more modest evolution or even a decrease. In 2016 values, the Basic Component went 
from R$1.6 billion to R$1.2 billion (decrease of 25%), the Strategic Component went from 
R$3.2 billion to approximately R$5 billion (increase of 53%), and the Specialized Component 
went from R$4.9 billion to R$6.7 billion (increase of 36%).
The availability of financial resources to ensure access to drugs matters a lot, as does their use. 
For this reason, since the 1970s, the World Health Organization has included in the concept 
of essential drugs and the rational use of drugs the relevance of comparing the effectiveness 
of products to the costs and ensuring the lowest cost for patients and their communitiesh,i. 
That is why we use economic evaluations, which compare the costs and results of each policy 
or technology option before its implementation or incorporation.
Resources are in fact scarce to meet the many needs of the population and therefore need 
to be used rationally, which again refers to the discussion about integrality in the SUS. There 
seems to be a consensus among Brazilian bioethicists that the universal right to health is 
a fundamental principle but that integrality must be regulated19. The allocation of scarce 
resources should be done with popular participation, considering the facts, principles, values, 
emotions, ideas, and beliefs of society20.
Regarding government responses to health problems and the needs of specific groups, we 
also identified important gaps, especially regarding the treatment of some rare diseases and 
alternatives for patients who cannot use the drugs listed in RENAME. In addition, insufficient 
financing of the SUS, sanitary and economic regulation, aging of the population, release of 
new drugs, management of health technologies, and financial sustainability of the system 
are important issues for public managers.
Thus, there are still major challenges to ensure the ITPC in the SUS, either in the sense of 
professional practices, the organization of actions and services, or in the governmental 
response to health problems or specific groups. This requires structuring actions and efficient 
use of available resources by Governments.
h Organización Mundial 
de la Salud. Selección de 
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Geneva: WHO; 2002. 
(WHO Policy Perspectives on 
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Box. Models of management of pharmaceutical care and possible consequences for the access to drugs and public administration.
Models of 
management of 
pharmaceutical care
Example Access to drugs
Some possible difficulties from the perspective of the 
public administration
State public 
management
State public pharmaceutical 
care (most of the Brazilian 
municipalities)
It depends on the performance of 
the Health Department team in 
the management of the logistics 
component and the regular 
financing of the procurements
•Management of procurement processes
•Difficulties in complying with distribution schedules
•Lack of drugs in health units
Integrated public 
and private mix
Management of health units, 
including pharmacies, by social 
organizations (OSS), but the global 
management of pharmaceutical 
care is under the responsibility of 
the public administration 
It depends on the performance of 
the Health Department team in 
the management of the logistics 
component of pharmaceutical 
care and the routine financing of 
the procurements
•The problems mentioned above may arise because the 
logistical component of pharmaceutical care falls under 
the responsibility of the public administration
•Difficulties in coordinating the actions of the technical 
component (the OSS is responsible for the management 
of the health unit and the pharmacists are hired by it)
Segmented public 
and private mix
Public or state public 
pharmaceutical care from the 
OSS coexisting with the Popular 
Pharmacy Program
It is facilitated by the supply of 
drugs by the private network of 
pharmaceutical establishments 
(drugstores)
•Overlapping programs with different costs for the same 
paying source and induction of the market to ensure the 
offering only by the program that is more profitable
•Costs may be higher than in other models
•Difficulties in the regulation and control of expenses
•Disarticulation between the technical and logistic 
components of pharmaceutical care
•Pharmacotherapeutic monitoring by the public 
administration is impaired, unless mechanisms are 
created to link the health services of the SUS to the 
private network
•Fragmentation of the care may be greater
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Regarding the delimitation of the access to drugs, we should consider the establishment of 
criteria for the regulation of the access of patients in exceptional situations that are not in the 
lists of the SUS. However, before that, some consensus on this subject should be established. 
It is unreasonable for the SUS to offer experimental drugs that are not proven to be effective 
and safe or that can be replaced by other drugs already available in the lists. In addition, the 
cost of treatment also needs to be considered. If the issues involving the allocation of scarce 
resources from society ethically require popular participation, would it not be the time to 
hold a national pharmaceutical care conference to discuss these issues?
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